

Bakers Union and FELRA Health and Welfare fund

Quarterly Review
January – June 2021

September 8, 2021

Agenda: 2Q2021 Quarterly Review

Agenda

1. Key Discussion Topics

2. Performance Summary

3. Trend

4. Top Disease States

5. Savings Outcomes
a. Clinical Outcomes
b. Vigilant Drug Outcomes

6. Clinical Opportunities
a. Specialty-Split-Fill/Smart-Fill

Your OptumRx Team



Holly Agoney

Strategic Account Executive



Ernesto Escobedo

Pharmacy Account Management



Fabian Gonzalez

Pharmacy Service Specialist



Adam Towner

Sr. Director, Client Management

Current Plan Design

☐ Deductible, Ben Max, MOOP, Copays

Plan 1 (group BFWRX):	
Deductible:	This plan has no deductible.
Benefit Maximum:	\$2,000 per year for Growth Hormones medications only
Max out of Pocket:	\$2,850 Individual / \$5,700 Family

Plan 2 (group BFWRX2) & Plan 3 (group BFWRX3):	
Deductible:	This plan has no deductible.
Benefit Maximum:	\$2,000 per year for Growth Hormones medications only
Max out of Pocket:	\$1,850 Individual / \$3,700 Family

Co-pays

Plan 1 (group BFWRX) & Plan 2 (group BFWRX2):			
Retail		Mail	
*Generic:	\$10	*Generic:	\$20
*Brand:	\$15	*Brand:	\$30
*NP Brand:	\$30	*NP Brand:	\$60
*Specialty:	Run trial claim for co-pay	*Specialty:	N/A

Plan 3 (group BFWRX3):		
Retail / Mail		
*Generic:	5%	(\$5 min.)
*Brand:	15%	(\$15 min.)
*NP Brand:	25%	(\$25 min.)
*Specialty:	Run trial claim for co-pay	

☐ Premium Formulary (7/1/2021)

☐ Effective 7/1/19

- ☐ Diabetes Program
- ☐ Comprehensive Ums
- ☐ Vigilant Program
- ☐ RxOTC Program

☐ Effective 8/1/2020

- ☐ Orphan Drug Program

☐ Effective 3/1/2021

- ☐ Opioid Mgmt – tighter refill window & UMs

☐ Effective 7/1/2021


- ☐ Mandatory Mail - MSS

Key Discussion Topics

- ❑ Per Member Per Month (PMPM) trend = -13.6% Specialty trend = -34%
- ❑ Specialty accounted for 0.7% of claims
- ❑ Top 5 disease states accounted for 76% of total plan paid
 - ❑ Top traditional disease state: Diabetes
 - ❑ Top specialty disease state: Inflammatory Conditions
- ❑ Clinical Outcome Savings - \$140,400
 - ❑ This is for all PA, ST, QL currently in place
- ❑ Vigilant Outcome Savings - \$31,176

Key Statistics - Performance Summary

Client totals



The key metrics here help highlight the changes Bakers Union and FELRA Health and Welfare Fund has experienced period over period.

- Eligibility has decreased by -12.
- Number of utilizers has increased by 81.

Total Rx's

CURRENT

4,739

PREVIOUS

4,275

PERCENT CHANGE

10.9%

Total plan paid

CURRENT

\$472,688

PREVIOUS

\$557,034

PERCENT CHANGE

-15.1%

Utilizers

CURRENT

464

PREVIOUS

383

PERCENT CHANGE

21.1%

Key Statistics with Benchmark Comparison

Key statistics with benchmark comparison

Benchmark comparison 1

LABOR AND TRUST

Benchmark comparison 2

COMMERCIAL


Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was -13.6%, compared to the benchmark trend of 5.7%
- Member Paid Share changed by 17.2% period over period, compared to the benchmark of 1.5%

Key statistics	Curr	Prev	Percent change	Curr	Percent change	Curr	Percent change
Average age	42.0	41.5	1.2%	36.3	-4.0%	36.1	-2.0%
Plan paid PMPM	\$114.84	\$132.91	-13.6%	\$97.69	5.7%	\$105.05	7.5%
Plan paid per Rx	\$99.74	\$130.30	-23.5%	\$125.12	4.5%	\$130.72	6.2%
Rxs PMPM	1,151	1,020	12.9%	0.781	1.2%	0.804	1.2%
Average days supply	26.9	27.0	-0.4%	37.9	-1.0%	38.4	-1.6%
Days supply PMPM	31.0	27.6	12.4%	29.6	0.2%	30.9	-0.4%
Member paid share	8.4%	7.2%	17.2%	12.0%	1.5%	13.1%	-2.0%
Member paid per Rx	\$9.19	\$10.11	-9.1%	\$17.08	6.3%	\$19.71	3.7%
Generic dispensing rate	78.9%	85.0%	-7.2%	85.3%	-2.7%	84.0%	-4.5%
Home delivery rate	1.2%	1.1%	10.9%	7.9%	3.3%	5.7%	0.8%
Retail 90 rate	3.8%	0.3%	1,359.8%	12.1%	4.2%	17.7%	3.3%
Tier 3 rate	0.0%	0.0%	N/A	2.9%	27.9%	3.3%	42.8%
Percent of specialty plan paid	33.2%	43.4%	-23.6%	45.3%	6.4%	50.6%	4.4%

Key Specialty Statistics

Client totals



The key metrics here help highlight the changes Bakers Union and FELRA Health and Welfare Fund has experienced period over period.

- Eligibility has decreased by -12.
- Number of utilizers has decreased by -6.

Total Rx's

CURRENT

33

PREVIOUS

38

PERCENT CHANGE

-13.2%

Total plan paid

CURRENT

\$156,829

PREVIOUS

\$241,859

PERCENT CHANGE

-35.2%

Utilizers

CURRENT

5

PREVIOUS

11

PERCENT CHANGE

-54.5%

Key Specialty Statistics with Benchmark Comparison

Key statistics with benchmark comparison

Benchmark comparison 1

LABOR AND TRUST

Benchmark comparison 2

COMMERCIAL

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was -34.0%, compared to the benchmark trend of 12.5%
- Member Paid Share changed by 29.3% period over period, compared to the benchmark of 26.0%

Key statistics	Curr	Prev	Percent change	Curr	Percent change	Curr	Percent change
Average age	42.0	41.5	1.2%	36.3	-4.0%	36.1	-2.0%
Plan paid PMPM	\$38.10	\$57.71	-34.0%	\$44.22	12.5%	\$53.13	12.2%
Plan paid per Rx	\$4,752.40	\$6,364.71	-25.3%	\$5,775.21	4.1%	\$5,680.06	2.5%
Rxs PMPM	0.008	0.009	-11.6%	0.008	8.0%	0.009	9.5%
Average days supply	29.2	30.1	-3.0%	31.9	-0.1%	31.9	-0.9%
Days supply PMPM	0.2	0.3	-14.2%	0.2	7.9%	0.3	8.5%
Member paid share	0.3%	0.2%	29.3%	7.3%	26.0%	6.5%	20.1%
Member paid per Rx	\$14.24	\$14.74	-3.4%	\$455.44	33.2%	\$395.80	24.6%
Generic dispensing rate	15.2%	5.3%	187.9%	22.6%	-5.9%	21.5%	-6.5%
Home delivery rate	0.0%	0.0%	0.0%	1.9%	-3.2%	1.7%	-6.8%
Retail 90 rate	0.0%	2.6%	-100.0%	4.4%	-4.5%	5.4%	-4.8%
Tier 3 rate	N/A	N/A	N/A	14.2%	-2.6%	13.8%	-4.1%

Trend Summary

Your benchmark comparison

LABOR AND TRUST ▼

Trend

Plan paid PMPM has decreased -13.6% over the previous period driven primarily by utilization in traditional and drug mix for specialty.

Specialty represents 0.7% of claims.



-19.3% under benchmark +1.3% over benchmark -46.5% under benchmark


Total Trend Components

Your benchmark comparison

LABOR AND TRUST ▼

Total trend: **-13.6%**


- Bakers Union and FELRA Health and Welfare Fund's overall trend of -13.6% was -19.3% lower than benchmark
- Specialty spend influenced the trend contributing 108.5% (15.8% higher than benchmark)
- Traditional trend contributed -8.5% (15.8% lower than benchmark)



Traditional vs. Specialty Trend Components


Traditional trend: 2.0%

- Traditional trend contributed -8.5% to the overall trend (-13.6%)
- Traditional accounts for 66.8% of overall total plan paid and was up from 56.6% in the prior period



Specialty trend: -34.0%

- Specialty trend contributed 108.5% to the overall trend (-13.6%)
- Specialty accounts for 33.2% of overall total plan paid and was up from 43.4% in the prior period



Top Disease States

Top 5 disease states account for 76% of total Plan Paid

- Inflammatory Conditions accounts for 33.2% of total plan paid, with trend driven by Utilization. TREMFYA was the top drug
- Diabetes accounts for 23.9% of total plan paid, with trend driven by Utilization. VICTOZA was the top drug

Traditional

Specialty

Sort by: Plan Paid Contribution to trend

Inflammatory Conditions ▼

PMPM
\$38.16

Trend
-14.8%

Top driver:
Utilization

Diabetes ▲

PMPM
\$27.43

Trend
17.0%

Top driver:
Utilization

HIV ▲

PMPM
\$9.53

Trend
36.8%

Top driver:
Utilization

Cardiovascular ▼

PMPM
\$7.05

Trend
-5.1%

Top driver:
Utilization

Asthma / COPD ▼

PMPM
\$5.20

Trend
-25.1%

Top driver:
Utilization

All other ▼

PMPM
\$27.47

Trend
-36.6%

Top 20 Drugs

Traditional

Specialty

Rank														Trend components		
Cu	Pv	Bench	Drug name	Therapy class	Utilizr	Rxcs	Avg days supply	Total plan paid	Plan paid per Rx	Curr PMPM	Prev PMPM	Bench PMPM	% Trend	Top driver	% Top driver	
1	3	19	TREMFYA	Chronic Inflammatory Disease	1	4	30.0	\$48,941	\$12,235.13	\$11.89	\$8.32	\$0.89	42.9%	Utilzn	35.8%	
2	1	1	HUMIRA PEN	Chronic Inflammatory Disease	1	7	28.0	\$43,260	\$6,179.97	\$10.51	\$16.47	\$6.36	-36.2%	Utilzn	-40.6%	
3	4	16	OTEZLA	Chronic Inflammatory Disease	2	10	30.0	\$39,339	\$3,933.89	\$9.56	\$7.93	\$0.96	20.6%	Utilzn	13.1%	
4	7	8	DUPIXENT	Chronic Inflammatory Disease	1	7	28.0	\$23,574	\$3,367.78	\$5.73	\$4.68	\$1.41	22.4%	Utilzn	18.8%	
5	6	394	STRIBILD	HIV-Multiclass Combo	1	5	30.0	\$17,349	\$3,469.81	\$4.22	\$4.76	\$0.04	-11.5%	Utilzn	-15.1%	
6	-	17	BIKTARVY	HIV-Multiclass Combo	1	4	30.0	\$11,733	\$2,933.15	\$2.85	\$0.00	\$0.93	-	-	-	
7	10	21	VICTOZA	GLP-1 Receptor Agonists	2	12	30.0	\$11,680	\$973.33	\$2.84	\$2.47	\$0.87	14.8%	Utilzn	11.1%	
8	11	7	JANUVIA	DPP-4 Inhibitors & Combos	7	23	29.4	\$10,606	\$461.14	\$2.58	\$2.18	\$1.64	18.1%	Utilzn	13.9%	
9	9	872	HUMALOG MIX 50/50 KWIKPEN	Insulin	2	5	65.2	\$9,322	\$1,864.44	\$2.26	\$2.90	\$0.01	-21.8%	Drug Mix	-9.7%	
10	16	102	LANTUS	Insulin	2	10	38.0	\$9,253	\$925.32	\$2.25	\$1.58	\$0.20	42.5%	Utilzn	61.2%	
11	13	4	JARDIANCE	SGLT-2 Inhibitors & Combos	3	15	30.0	\$8,920	\$594.64	\$2.17	\$1.68	\$2.15	29.2%	Cost	19.6%	
12	475	259	PREZCOBIX	HIV-Multiclass Combo	1	4	30.0	\$7,941	\$1,985.35	\$1.93	\$0.00	\$0.06	0.0%	Cost	0.0%	
13	-	40	PFIZER-BIONTECH COVID-19 VACCINE	COVID-19 Vaccines	145	277	1.0	\$7,522	\$27.15	\$1.83	\$0.00	\$0.44	-	-	-	
14	480	3	TRULICITY	GLP-1 Receptor Agonists	2	8	28.0	\$6,507	\$813.33	\$1.58	-\$0.18	\$2.34	-999.8%	Utilzn	-914.6%	
15	25	22	JANUMET	DPP-4 Inhibitors & Combos	3	13	30.0	\$6,111	\$470.07	\$1.48	\$0.97	\$0.80	52.3%	Utilzn	47.1%	
16	-	5	OZEMPIC	GLP-1 Receptor Agonists	1	7	30.0	\$5,700	\$814.29	\$1.38	\$0.00	\$1.91	-	-	-	
17	21	42	ENTRESTO	Angiotensin II Receptor & Nephrylsin Inhibitor (ARNI)	2	10	30.0	\$5,526	\$552.56	\$1.34	\$1.12	\$0.42	20.1%	Utilzn	13.1%	
18	-	53	MODERNA COVID-19 VACCINE	COVID-19 Vaccines	108	205	1.0	\$5,346	\$26.08	\$1.30	\$0.00	\$0.34	-	-	-	
19	22	66	DEXILANT	Proton Pump Inhibitors	3	18	30.0	\$5,177	\$287.62	\$1.26	\$1.09	\$0.28	14.9%	Utilzn	7.8%	
20	15	27	SYMBICORT	Inhaled Asthma/COPD Combo	4	12	35.0	\$4,746	\$395.48	\$1.15	\$1.65	\$0.60	-30.3%	Utilzn	-32.1%	
Total					271	656	9.1	\$288,552	\$439.87	\$70.10	\$57.63	\$22.62	21.6%		30.6%	
Plan Total					464	4,739	26.9	\$472,688	\$99.74	\$114.84	\$132.91	\$97.69	-13.6%		-22.0%	

17 out of the top 20 drugs have moved up in rank

Top 20 Traditional Drugs

Rank													Trend components		
Cu	Pv	Bench	Drug name	Therapy class	Utilzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr PMPM	Prev PMPM	Bench PMPM	% Trend	Top driver	% Top driver
1	1	224	STRIBILD	HIV-Multiclass Combo	1	5	30.0	\$17,349	\$3,469.81	\$4.22	\$4.76	\$0.04	-11.5%	Utilzn	-15.1%
2	-	8	BIKTARVY	HIV-Multiclass Combo	1	4	30.0	\$11,733	\$2,933.15	\$2.85	\$0.00	\$0.93	-	-	-
3	3	10	VICTOZA ★	GLP-1 Receptor Agonists	2	12	30.0	\$11,680	\$973.33	\$2.84	\$2.47	\$0.87	14.8%	Utilzn	11.1%
4	4	5	JANUVIA ★	DPP-4 Inhibitors & Combos	7	23	29.4	\$10,606	\$461.14	\$2.58	\$2.18	\$1.64	18.1%	Utilzn	13.9%
5	2	606	HUMALOG MIX 50/50 KWIKPEN ★	Insulin	2	5	65.2	\$9,322	\$1,864.44	\$2.26	\$2.90	\$0.01	-21.8%	Drug Mix	-9.7%
6	9	58	LANTUS ★	Insulin	2	10	38.0	\$9,253	\$925.32	\$2.25	\$1.58	\$0.20	42.5%	Utilzn	61.2%
7	6	2	JARDIANCE ★	SGLT-2 Inhibitors & Combos	3	15	30.0	\$8,920	\$594.64	\$2.17	\$1.68	\$2.15	29.2%	Cost	19.6%
8	465	130	PREZCOBIX	HIV-Multiclass Combo	1	4	30.0	\$7,941	\$1,985.35	\$1.93	\$0.00	\$0.06	0.0%	Cost	0.0%
9	-	19	PFIZER-BIONTECH COVID-19 VACCINE	COVID-19 Vaccines	145	277	1.0	\$7,522	\$27.15	\$1.83	\$0.00	\$0.44	-	-	-
10	470	1	TRULICITY ★	GLP-1 Receptor Agonists	2	8	28.0	\$6,507	\$813.33	\$1.58	-\$0.18	\$2.34	-999.8%	Utilzn	-914.6%
11	18	11	JANUMET ★	DPP-4 Inhibitors & Combos	3	13	30.0	\$6,111	\$470.07	\$1.48	\$0.97	\$0.80	52.3%	Utilzn	47.1%
12	-	3	OZEMPIC ★	GLP-1 Receptor Agonists	1	7	30.0	\$5,700	\$814.29	\$1.38	\$0.00	\$1.91	-	-	-
13	14	21	ENTRESTO	Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	2	10	30.0	\$5,526	\$552.56	\$1.34	\$1.12	\$0.42	20.1%	Utilzn	13.1%
14	-	26	MODERNA COVID-19 VACCINE	COVID-19 Vaccines	108	205	1.0	\$5,346	\$26.08	\$1.30	\$0.00	\$0.34	-	-	-
15	15	36	DEXILANT	Proton Pump Inhibitors	3	18	30.0	\$5,177	\$287.62	\$1.26	\$1.09	\$0.28	14.9%	Utilzn	7.8%
16	8	14	SYMBICORT	Inhaled Asthma/COPD Combo	4	12	35.0	\$4,746	\$395.48	\$1.15	\$1.65	\$0.60	-30.3%	Utilzn	-32.1%
17	17	33	BYDUREON BCISE ★	GLP-1 Receptor Agonists	1	6	28.0	\$4,362	\$727.07	\$1.06	\$1.00	\$0.29	6.0%	Cost	4.1%
18	-	12	FARXIGA ★	SGLT-2 Inhibitors & Combos	3	4	60.0	\$4,136	\$1,033.92	\$1.00	\$0.00	\$0.80	-	-	-
19	19	6	LANTUS SOLOSTAR ★	Insulin	4	10	30.9	\$3,781	\$378.11	\$0.92	\$0.85	\$1.35	8.6%	Cost	18.3%
20	7	59	REXULTI	Atypical Antipsychotics	1	4	30.0	\$3,731	\$932.84	\$0.91	\$1.68	\$0.19	-45.9%	Utilzn	-41.8%
Total					272	652	9.2	\$149,449	\$229.22	\$36.31	\$23.75	\$15.63	52.9%		35.7%
Plan Total					464	4,706	26.9	\$315,859	\$67.12	\$76.74	\$75.20	\$53.47	2.0%		12.7%

Top 20 Specialty Drugs

Rank													Trend components		
Cu ↕	Pv ↕	Bench ↕	Drug name ↕	Therapy class ↕	Utlzr ↕	Rxs ↕	Avg days supply ↕	Total plan paid ↕	Plan paid per Rx ↕	Curr PMPM ↕	Prev PMPM ↕	Bench PMPM ↕	% Trend ↕	Top driver ↕	% Top driver ↕
1	3	11	TREMFYA	Chronic Inflammatory Disease	1	4	30.0	\$48,941	\$12,235.13	\$11.89	\$8.32	\$0.89	42.9%	Utlzn	35.8%
2	1	1	HUMIRA PEN	Chronic Inflammatory Disease	1	7	28.0	\$43,260	\$6,179.97	\$10.51	\$16.47	\$6.36	-36.2%	Utlzn	-40.6%
3	4	9	OTEZLA	Chronic Inflammatory Disease	2	10	30.0	\$39,339	\$3,933.89	\$9.56	\$7.93	\$0.96	20.6%	Utlzn	13.1%
4	6	3	DUPIXENT	Chronic Inflammatory Disease	1	7	28.0	\$23,574	\$3,367.78	\$5.73	\$4.68	\$1.41	22.4%	Utlzn	18.8%
5	8	84	MYCOPHENOLATE MOFETIL	Transplant	1	5	30.0	\$1,715	\$343.09	\$0.42	\$0.10	\$0.10	304.9%	Utlzn	409.1%
Total					5	33	29.2	\$156,829	\$4,752.40	\$38.10	\$57.71	\$10.45	-34.0%		-25.9%
Plan Total					5	33	29.2	\$156,829	\$4,752.40	\$38.10	\$57.71	\$44.22	-34.0%		-25.9%

Clinical Outcomes

Clinical Outcomes

Outcomes date range: Jul 2020 - Jun 2021

Utilization management savings: \$17.11 PMPM

Your program savings: **\$140.4K**

Ensuring patients meet appropriate clinical criteria when initiating medication therapy not only helps to ensure that the patient is being treated safely according to guidelines, but also drives significant savings for both Bakers Union and FELRA Health and Welfare Fund and for members. Bakers Union and FELRA Health and Welfare Fund has realized over \$140.4K in savings. Based on a study by OptumRx, leveraging UM strategies that drive members to appropriate and often lower cost medications for treatment can save a member up to \$620 annually in out of pocket copayments.

n

● Prior auth ● Quantity limits ● Step therapy



Prior authorization

PMPM SAVINGS

\$8.52

NUMBER OF MEMBERS IMPACTED

28

NUMBER OF INTERVENTIONS

35

Quantity limits

PMPM SAVINGS

\$0.15

NUMBER OF MEMBERS IMPACTED

6

NUMBER OF INTERVENTIONS

6

Step therapy

PMPM SAVINGS

\$8.44

NUMBER OF MEMBERS IMPACTED

92

NUMBER OF INTERVENTIONS

124

QL savings is based only on Maximum Daily Dose edits.

Vigilant Program - Outcomes

Outcomes date range: Jan - Jun 2021

Vigilant Drug Outcomes – Cost Avoidance

By leveraging the Vigilant Drug Program, Bakers Union and FELRA Health and Welfare Fund has:

- Avoided \$31.2K in pharmacy spend
- Switched 6 claims to lower cost alternatives
- 17 claims were abandoned



TOTAL PLAN PAID SAVINGS

\$31,176

TOTAL PROGRAM SAVINGS

6.6%

TOTAL MEMBERS IMPACTED

24

Savings by Vigilant Drug List

Sort by: Members impacted Plan paid PMPM savings

Vigilant drug list	PMPM savings	Members impacted	Interventions
High Cost Generics	\$1.94	8	8
Clinical Duplicates	\$0.51	6	7
High Cost Brands with Generics	\$1.14	4	4
Non-FDA Approved Drugs	\$0.07	4	4
New Drugs to Market	\$0.15	2	2

Clinical Opportunities

“Specialty”
Split-fill and
Smart-fill (90-day)
Programs

Specialty - Split-fill and Smart-fill (90-day) Programs

Split fill and 90-day supply solutions

	Split Fill (1/2 Monthly Supply)	90-Day Supply
Conditions/Drugs	Oral oncology	MS, Inflammatory, Transplant
Patient Stability	Unstable on medication	Stable on medication
Clinical Intent	Adjust to medication	Adherence
Program Intent	Avoid waste	Member convenience
Member Experience	Increased clinical oversight	Improved satisfaction
# Fills/Duration	6 fills over first 3 months	4 fills over 12 months
Copays	½ copay	3x copay
Opt in	No (mandatory)	Yes (voluntary)
Program Offering	✓ Exclusivity program required ✓ No grace fills allowed	

BrivoRx Smart Fill Program

Client Pricing

Program	Split Fill	90-Day Supply	BrivoRx Exclusivity	Fee
STANDARD	X	X	X	FREE
NON-STANDARD	X	NO	X	\$70 per Split Fill Rx

Program requirements

- Exclusivity required for individual or combined program offering
- Program offered as a bundle only (Split Fill + 90-Day Supply)

Pricing options

- **Standard:** No charge for bundle offering.
- **Non-standard:** \$70 per Split Fill Rx fee for clients opting for Split Fill only

Split fill

Oncology medications: high discontinuation

Toxic side effects from oral oncology medications lead to high discontinuation rates

Standard split fill drug list

- Afinitor® (everolimus)
- Afinitor Disperz®
- Bosulif®
- Brukinsa®
- Cabometyx®
- Cometriq®
- Daurismo®
- Erivedge®
- Inlyta®
- Inrebic®
- Lenvima®
- Lorbrena®
- Nerlynx®
- Nexavar®
- Nubeqa®
- Odomzo®
- Rozlytrek®
- Sprycel®
- Talzenna®
- Tarceva® (erlotinib)
- Targretin® (bexarotene)
- Verzenio®
- Vizimipro®
- Votrient®
- Xalkori®
- Xtandi®
- Zejula®
- Zolanza®
- Zykadia®
- Zytiga® (abiraterone)

Increase in medication waste



49%

discontinue therapy
within 90 days*

Split-fill Program

Split fill client impact



Savings

~50% of drug cost/member*
clients who implement split fills
may save money from waste avoidance



Copays

Shorter fills, smaller copays
no wasted medicine =
no wasted money for members



Exclusivity

**Optum Specialty
Pharmacy**
exclusivity required



Grace Fills

No grace fills allowed

Smart-fill (90-day) Program

90-day supply

90 DAY SUMMARY (Members who have consecutively filled for at least 6 months)

Total number of utilizers	Duration of data pulled	Eligible members
5	7 Months	2

Patients who have proven to remain adherent to select medications and meet eligibility requirements may request 90-day refills

Top class and drug examples

Multiple Sclerosis

Ampyra
Copaxone
Gilenya
Tecfidera

Inflammatory Conditions

Enbrel
Humira
Orencia
Simponi

Transplant


azathioprine
mycophenolate
Prograf
Tacrolimus

Smart-fill (90-day) Program

90-day supply

Long-term conditions

For members who have a chronic condition and are stable on therapy, there is less risk of waste



Therapeutic Classes

- Multiple Sclerosis
- Transplant
- Inflammatory Conditions

30-Day Supply

12 Refills



12 total copays / one copay per refill

90-Day Supply

4 Refills



12 total copays / three copays per refill

- ✓ Opt-in
- ✓ Enhanced member convenience
- ✓ Adherence monitoring
- ✓ Improved member satisfaction

Smart-fill (90-day) Program

90-day supply member experience

90-Day Fill



Member Outreach



Members stable to therapy for six months are given option to receive 90-day supply

Member Chooses 90-day

Member Declines 90-Day



Care coordinator contacts every three months
Screen for adherence



Care coordinator contacts once per month
Screen for adherence

As part of our clinical management program, members receive additional, regular monitoring and support to ensure they are successful on their treatment regimens.